Mammogen Appoints Diagnostics Industry Leader Dr. Robert S. Epstein
News related to:Mammogen · 1 min read
NEWPORT BEACH, Calif., Oct. 13, 2026 /CourierPR/ -- Mammogen, a precision health diagnostics company, has appointed Dr. Robert S. Epstein to its Board of Directors. With over two decades of experience in shaping the scientific, commercial, and market success of leading genomics, precision oncology, and women's health companies, Dr. Epstein brings a wealth of knowledge to Mammogen as it advances its genTRU-breast assay.
Dr. Epstein's extensive background includes serving as Chairman of Veracyte, a company that has evolved into a major player in cancer diagnostics. His tenure at Veracyte, where he guided the company through significant growth, underscores his expertise in commercializing breakthrough scientific discoveries. Additionally, he previously served as Chairman of Decipher Biosciences, which was acquired by Veracyte, and currently sits on the Board of PinkDx, a company focused on women's gynecologic cancer diagnostics.
Elizabeth Cormier-May, Mammogen's Chief Executive Officer, highlighted the significance of Dr. Epstein's appointment.
Dr. Epstein's appointment comes at a critical juncture for Mammogen. The company is advancing its genTRU-breast assay, a novel blood-based assay designed to identify biological signals associated with breast cancer at its earliest stages. Through prospective clinical validation and commercialization, Mammogen aims to bring a new dimension to breast cancer detection, particularly for women with dense breast tissue.
DeeDee DeMan, Chairwoman of the Board of Mammogen, emphasized the strategic value of Dr. Epstein's experience.
Dr. Epstein's background in guiding companies through the transition from breakthrough science to clinically meaningful diagnostics is particularly relevant.
Mammogen's platform is built on scalable RNA biomarker discovery and computational interpretation, with a pipeline designed to expand into additional women's health applications over time. The company's lead product, genTRU-breast, is poised to complement imaging and support breast cancer detection, particularly in women with dense breast tissue.
Dr. Epstein's appointment further bolsters Mammogen's leadership as it advances toward prospective clinical readout and commercialization. His experience spans the full arc of diagnostics innovation, from scientific validation and clinical adoption to commercial scale and category leadership.